Peptides
Peptide Safety, Stated Honestly
For most compounds in this category there is no human safety data at all. That is the headline, not a footnote — and it changes what a safety article can responsibly say.
Dr. Priya Raghunathan
Priya is a clinical pharmacologist. She writes occasional guest pieces here, usually when something in the consumer wellness market has outrun its evidence base.
11 articles by Dr. Priya Raghunathan
Peptides
The Thousandfold Error
The most preventable harm in this category is not pharmacological. It is a unit conversion done wrong — and the same mistake, made the same way, produces a dose a thousand times too large.
Peptides
Reconstitution: Which Rules Are Real
The standard guidance is a mix of genuine sterile compounding practice and folklore repeated until it hardened. The two are worth separating, because only one of them prevents infections.
Peptides
Nasal Delivery, and the Numbers Nobody Measured
Route-of-administration guides for peptides circulate with impressive precision — bioavailability percentages, dose multipliers, brain-level comparisons. Most of those numbers have no study behind them.
Peptides
What Goes Wrong at the Injection Site
Subcutaneous technique is standard patient-education material and worth getting right. The failure modes are specific, well documented, and almost entirely preventable.
Peptides
The Two Clocks
Reconstituting a vial starts two timers that measure completely different things. Almost every storage guide collapses them into one number, and that conflation is where the confusion lives.
Metabolic Health
Retatrutide: What the Trials Actually Show
The trial data is genuinely remarkable, the mechanism is elegant, and the compound is approved in no country on earth. All three of those things are true at once, and most coverage manages only the first.
Nootropics
Creatine Is Not Just for Lifters. The Cognitive Data, Assessed
The best-evidenced sports supplement of the last thirty years has a second literature attached to it. It is smaller, messier, and more interesting than either its promoters or its critics admit.
Nootropics
Modafinil, Honestly
Twenty years of research, a genuine effect, a real regulatory status, and a set of trade-offs that the productivity-blog framing consistently omits.
Sleep
Blue Light Blockers: Sorting the Evidence From the Marketing
The photoreceptor biology is genuinely elegant. The consumer product built on top of it is a much weaker proposition than the packaging suggests.
Longevity
Rapamycin, Metformin, and the Gap Between Mice and Us
Two drugs dominate the longevity conversation. The animal data behind one is genuinely impressive. Neither has shown a lifespan effect in a human being.